Elevated Lipoprotein Lipase Activity Does Not Account for the Association Between Adiponectin and HDL in Type 1 Diabetes.

CONTEXT Increased high-density lipoprotein cholesterol (HDL-C) is common in type 1 diabetes (T1D) and is associated both with hyperadiponectinemia and with elevated lipoprotein lipase activity (LPL). Because adiponectin has been shown to increase LPL expression, elevated LPL may link the hyperadiponectinemia in T1D with increased HDL. OBJECTIVE The purpose of this study was to determine whether LPL activity accounts for the association between adiponectin and HDL in T1D. DESIGN, PARTICIPANTS, AND SETTING A cohort of 127 patients with T1D attending the Diabetes Clinic at the University of Miami and 103 healthy control subjects were recruited. MAIN OUTCOME MEASURE HDL-C and adiponectin were measured in the full cohort and in a subgroup, HDL subfractions were obtained by ultracentrifugation, and LPL and hepatic lipase were measured in postheparin plasma. RESULTS Total HDL-C and the lowest density HDL subfraction, apolipoprotein A-I, LPL activity, and adiponectin levels were higher in subjects with T1D than in control subjects (P < .05). Both adiponectin and LPL activity were directly associated with total HDL-C and its lowest density subfraction, but adiponectin and LPL were not correlated (P = 0.13). Adiponectin alone explained 11.6% and adiponectin plus LPL explained 23.8% of the HDL-C variance. In a multivariate model, adiponectin remained an independent predictor of HDL-C along with LPL and serum creatinine, explaining together 27% of HDL-C variance. CONCLUSIONS Adiponectin was strongly associated with HDL-C in T1D, suggesting that hyperadiponectinemia is linked to the elevated HDL-C in this population. However, this relationship is independent of the association between LPL and HDL-C. Thus, elevated adiponectin and LPL activity are independently related to increased HDL-C in T1D.

[1]  R. Goldberg,et al.  High HDL-C prevalence is common in type 1 diabetes and increases with age but is lower in Hispanic individuals. , 2015, Journal of diabetes and its complications.

[2]  E. Barrett-Connor,et al.  Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. , 2013, The Journal of clinical endocrinology and metabolism.

[3]  S. Yamashita,et al.  Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography. , 2012, Metabolism: clinical and experimental.

[4]  M. Rewers,et al.  Adiponectin dysregulation and insulin resistance in type 1 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[5]  Merlin C. Thomas,et al.  Serum adiponectin concentration is a positive predictor of all‐cause and cardiovascular mortality in type 1 diabetes , 2011, Journal of internal medicine.

[6]  T. Orchard,et al.  High-density lipoprotein cholesterol in diabetes: is higher always better? , 2011, Journal of clinical lipidology.

[7]  J. Saltevo,et al.  High serum adiponectin is associated with favorable lipoprotein subclass profile in 6.4-year follow-up. , 2011, European journal of endocrinology.

[8]  C. Tschöpe,et al.  Impact of HDL on adipose tissue metabolism and adiponectin expression. , 2010, Atherosclerosis.

[9]  J. Frystyk,et al.  Adiponectin and Lipoprotein Particle Size , 2009, Diabetes Care.

[10]  J. Shao,et al.  Adiponectin Reduces Plasma Triglyceride by Increasing VLDL Triglyceride Catabolism , 2008, Diabetes.

[11]  J. Hokanson,et al.  Determinants of serum adiponectin in persons with and without type 1 diabetes. , 2007, American journal of epidemiology.

[12]  Michael J Pencina,et al.  Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study , 2007, Circulation.

[13]  P. Gambert,et al.  Adiponectin Is an Important Determinant of ApoA-I Catabolism , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[14]  J. Schneider,et al.  Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. , 2005, Diabetes care.

[15]  B. Wolffenbuttel,et al.  Post-heparin plasma lipoprotein lipase, but not hepatic lipase activity, is related to plasma adiponectin in type 2 diabetic patients and healthy subjects. , 2005, Clinical laboratory.

[16]  J. Schneider,et al.  Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. , 2004, Diabetes care.

[17]  T. Orchard,et al.  The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study , 2004, Diabetologia.

[18]  U. Müller-Ladner,et al.  Adiponectin represents an independent cardiovascular risk factor predicting serum HDL‐cholesterol levels in type 2 diabetes , 2003, FEBS letters.

[19]  M. Cnop,et al.  Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex , 2003, Diabetologia.

[20]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[21]  T. Funahashi,et al.  Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. , 2002, Diabetes care.

[22]  C. Bouchard,et al.  Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[23]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  J. Zhi,et al.  Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers , 2000, International Journal of Obesity.

[25]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[26]  A. Tall Metabolic and genetic control of HDL cholesterol levels , 1992, Journal of internal medicine.

[27]  Robert V Farese,et al.  Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans. , 1991, Metabolism: clinical and experimental.

[28]  T. A. Hughes,et al.  Rapid quantitative apolipoprotein analysis by gradient ultracentrifugation and reversed-phase high performance liquid chromatography. , 1988, Journal of lipid research.

[29]  L. Rand,et al.  Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. , 1987, The American journal of cardiology.

[30]  E. Nikkilä,et al.  Serum Lipids and Lipoproteins in Insulin-treated Diabetes: Demonstration of Increased High Density Lipoprotein Concentrations , 1978, Diabetes.